Liesap

Active

Private limited companyfounded 20214 yrs activeWanzelesteenweg 98, 9260 Wichelen, BelgiumKBO/BCE: BE 0776.459.858

The computed 12-month bankruptcy probability of Liesap is 1.8% (moderate). The 2025 annual accounts show equity of €17k and a net result of €7k. Equity is shrinking by ~3.9% per year across the filed fiscal years. Its solvency ranks better than 40% of 18016 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Score 2025

53 / 100

Fair▼ -33 vs 2024

The score combines four axes. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability100▲+71

Solvency31▼-69

Growth32▼-20

Stability94

Bankruptcy probability, 12 months

1.8% Moderate

0%0.5%1.5%4%10%≥ 25%

Credit up to €1k at 30 days acceptable

Liquidity short (current ratio 0.94 against 2.57 in 2024), and 77% of the assets are financed with debt.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Limited track record

This company has not been active as long as an established one and statistically fails somewhat more often.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 47

Relative position

BE, all sectors

reference

Sector 47

higher

← fewer bankruptcies more bankruptcies →

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

23%

Return on assets

9.3%

Age of the figures

8 mo

Filed after the deadline

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

NBB · 4 filings

Deviation from the deadline

2025

28 d late

2024

29 d late

2023

30 d late

2022

31 d late

← before the deadline after the deadline →

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

14-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, micro schema

Equity

€17k▼ 66.7%

2024 · €50k

2022: €35k 2023: €47k 2024: €50k

2022 → 2025

Total assets

€72k▼ 5.8%

2024 · €77k

2022: €45k 2023: €85k 2024: €77k

2022 → 2025

Net result

€7k▲ 130%

2024 · €3k

2022: €32k 2023: €12k 2024: €3k

2022 → 2025

Working capital

€-3k

2024 · €27k

2022: €33k 2023: €22k 2024: €27k

2022 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line2022202320242025Trend

Equity€35k-€47k▲ 34.6%€50k▲ 6.2%€17k▼ 66.7%

Operating result€40k-€16k▼ 60.6%€5k▼ 68.8%€10k▲ 98.3%

Net result€32k-€12k▼ 62.1%€3k▼ 75.9%€7k▲ 130%

Turnover and EBIT margin not published: the micro schema does not require them.

Result per fiscal year

Operating resultNet result

The operating result recovers in 2025; 2025 is 98% above 2024.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €72k

31.3%

68.7%

Fixed assets €23k▼ 29.1%

Current assets €50k▲ 10.8%

Equity and liabilities €72k

23.0%

77.0%

Equity €17k▼ 66.7%

Debt €56k▲ 108%

The debt ratio rises from 34.8% to 77.0%: debt grows while equity shrinks.

Key figures and ratios

2025 value · change against 2024

EBITDA

€19k▲

2024 · €15k

Cash flow

€16k▲

2024 · €13k

Solvency

23.0%▼

2024 · 65.2%

Current ratio

0.94▼

2024 · 2.57

Quick ratio

0.94▼

2024 · 2.57

Debt / equity

3.34▲

2024 · 0.53

ROE

40.3%▲

2024 · 5.8%

ROA

9.3%▲

2024 · 3.8%

Interest coverage

36.06▲

2024 · 18.94

Debt

€56k▲

2024 · €27k

Debt ≤ 1 year

€53k▲

2024 · €17k

Debt > 1 year

€3k▼

2024 · €9k

Income taxes

€3k▲

2024 · €1k

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2025 against 2024

Balance sheet Code20242025

Assets

Total assets20/58€77k€72k▼

Fixed assets21/28€32k€23k▼

Tangible fixed assets22/27€31k€21k▼

Furniture and vehicles24€31k€21k▼

Financial fixed assets28€1k€1k=

Current assets29/58€45k€50k▲

Amounts receivable within one year40/41€11k€403▼

Other amounts receivable41€11k€403▼

Current investments50/53€25k€25k=

Cash at bank and in hand54/58€9k€24k▲

Equity and liabilities

Total equity and liabilities10/49€77k€72k▼

Equity10/15€50k€17k▼

Contributions10/11€3k€3k=

Reserves13€47k€7k▼

Distributable reserves133€47k€7k▼

Profit (loss) carried forward14-€7k

Amounts payable17/49€27k€56k▲

Amounts payable after more than one year17€9k€3k▼

Financial debts170/4€9k€3k▼

Amounts payable within one year42/48€17k€53k▲

Current portion of amounts payable after more than one year42€6k€7k▲

Trade debts44€1k€207▼

Suppliers440/4€1k€207▼

Taxes, remuneration and social security45€1k€2k▲

Taxes450/3€1k€2k▲

Other amounts payable47/48€9k€44k▲

Income statement Code20242025

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€10k€9k▼

Other operating charges640/8€141€274▲

Gross operating margin9900€15k€19k▲

Operating profit (loss)9901€5k€10k▲

Financial income75/76B€0€0▲

Recurring financial income75€0€0▲

Financial charges65/66B€781€530▼

Recurring financial charges65€781€530▼

Profit (loss) for the period before taxes9903€4k€9k▲

Income taxes67/77€1k€3k▲

Profit (loss) for the period9904€3k€7k▲

Profit (loss) for the period to be appropriated9905€3k€7k▲

Appropriation of the result

Profit (loss) to be appropriated9906€3k€7k▲

Transfer from equity791/2-€40k

Transfer to equity691/2€3k-

To other reserves6921€3k-

Profit to be distributed694/7-€40k

Return on contributions (dividend)694-€40k

The notes to these accounts (6 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 5Financial 1Filings 4

Next filing, fiscal year 2026, expected by 31-07-2027

2026

28-08

NBB filing Annual accounts filed

fiscal year 2025 · micro schema · 28 days late

2025

29-08

NBB filing Annual accounts filed

fiscal year 2024 · micro schema · 29 days late

2024

31-12

Financial Weakest financial yearnet €3k ▼75.9%

Net result drops to €3k, the lowest in the series; recovery starts the following year.

30-08

NBB filing Annual accounts filed

fiscal year 2023 · micro schema · 30 days late

2023

31-08

NBB filing Annual accounts filed

fiscal year 2022 · micro schema · 31 days late

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.

Location & real-estate footprint

Registered office, Wichelen · 1 establishment unit since 2021

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Wanzelesteenweg 989260 Wichelen

Ground area

674 m²

Building footprint

188 m²

Volume, LiDAR

993 m³

Parcel 42020C0050/00C000, Flanders · tallest building 9.4 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

Liesap

Wanzelesteenweg 98, 9260 WichelenRetail sale of pharmaceutical products

since 20212.324.376.950

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
42020C0050/00C000	Flanders	674 m²	1 · 188 m²	9.4 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Similar companies · same sector, comparable size

Bella Donna Pharma

BE 0649.552.976

Scherpenheuvel-Zichem · Eq €17k

PHARMACIE DU PRINCE D'ORANGE

Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 1,257 are within a factor 10 of this equity.See the whole sector

Company data · Crossroads Bank

Identification

Legal formPrivate limited company

Founded26-10-2021

Fiscal year end31-12

Activities, NACEBEL

47730Retail sale of pharmaceutical products

82100Office administrative and support services

82110Office administrative, office support and other business support activities

85599Other education

96999Other personal services

Sources

Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers

Data from official sources, last processed on 14-09-2026. Scores and ratios are computed by Checked and are not a credit decision.